Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jeanine J. Houwing-Duistermaat is active.

Publication


Featured researches published by Jeanine J. Houwing-Duistermaat.


American Journal of Human Genetics | 2001

PARK7, a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism, on Chromosome 1p36

C. M. van Duijn; Marieke C.J. Dekker; Vincenzo Bonifati; R.J. Galjaard; Jeanine J. Houwing-Duistermaat; Pieter J.L.M. Snijders; Leon Testers; Guido J. Breedveld; M.W.I.M. Horstink; Lodewijk A. Sandkuijl; J. C. van Swieten; B. A. Oostra; Peter Heutink

Although the role of genetic factors in the origin of Parkinson disease has long been disputed, several genes involved in autosomal dominant and recessive forms of the disease have been localized. Mutations associated with early-onset autosomal recessive parkinsonism have been identified in the Parkin gene, and recently a second gene, PARK6, involved in early-onset recessive parkinsonism was localized on chromosome 1p35-36. We identified a family segregating early-onset parkinsonism with multiple consanguinity loops in a genetically isolated population. Homozygosity mapping resulted in significant evidence for linkage on chromosome 1p36. Multipoint linkage analysis using MAPMAKER-HOMOZ generated a maximum LOD-score of 4.3, with nine markers spanning a disease haplotype of 16 cM. On the basis of several recombination events, the region defining the disease haplotype can be clearly separated, by > or =25 cM, from the more centromeric PARK6 locus on chromosome 1p35-36. Therefore, we conclude that we have identified on chromosome 1 a second locus, PARK7, involved in autosomal recessive, early-onset parkinsonism.


Genome Medicine | 2016

Making sense of big data in health research: Towards an EU action plan

Charles Auffray; Rudi Balling; Inês Barroso; László Bencze; Mikael Benson; Jay Bergeron; Enrique Bernal-Delgado; Niklas Blomberg; Christoph Bock; Ana Conesa; Susanna Del Signore; Christophe Delogne; Peter Devilee; Alberto Di Meglio; Marinus J.C. Eijkemans; Paul Flicek; Norbert Graf; Vera Grimm; Henk-Jan Guchelaar; Yike Guo; Ivo Gut; Allan Hanbury; Shahid Hanif; Ralf Dieter Hilgers; Ángel Honrado; D. Rod Hose; Jeanine J. Houwing-Duistermaat; Tim Hubbard; Sophie Helen Janacek; Haralampos Karanikas

Medicine and healthcare are undergoing profound changes. Whole-genome sequencing and high-resolution imaging technologies are key drivers of this rapid and crucial transformation. Technological innovation combined with automation and miniaturization has triggered an explosion in data production that will soon reach exabyte proportions. How are we going to deal with this exponential increase in data production? The potential of “big data” for improving health is enormous but, at the same time, we face a wide range of challenges to overcome urgently. Europe is very proud of its cultural diversity; however, exploitation of the data made available through advances in genomic medicine, imaging, and a wide range of mobile health applications or connected devices is hampered by numerous historical, technical, legal, and political barriers. European health systems and databases are diverse and fragmented. There is a lack of harmonization of data formats, processing, analysis, and data transfer, which leads to incompatibilities and lost opportunities. Legal frameworks for data sharing are evolving. Clinicians, researchers, and citizens need improved methods, tools, and training to generate, analyze, and query data effectively. Addressing these barriers will contribute to creating the European Single Market for health, which will improve health and healthcare for all Europeans.


Journal of Neurology, Neurosurgery, and Psychiatry | 2004

Octapeptide repeat insertions in the prion protein gene and early onset dementia

Esther A. Croes; Jessie Theuns; Jeanine J. Houwing-Duistermaat; Bart Dermaut; K Sleegers; Gerwin Roks; M Van den Broeck; B van Harten; J. C. van Swieten; Marc Cruts; C. Van Broeckhoven; C. M. van Duijn

Objectives: The most common familial early onset dementia mutations are found in the genes involved in Alzheimer’s disease; the amyloid precursor protein (APP) and the presenilin 1 and 2 (PSEN1 and 2) genes; the prion protein gene (PRNP) may be involved. Methods: Following identification of a two-octapeptide repeat insertion in PRNP, we conducted a meta-analysis to investigate the relation of number of PRNP octapeptide repeats with age at disease onset and duration of illness; identifying 55 patients with PRNP octapeptide repeat insertions. We used a linear mixed effects model to assess the relation of number of repeats with age at disease onset, and studied the effect of the number of inserted octapeptide repeats on disease duration with a Cox proportional hazards regression analysis. Results: We found an increasing number of repeats associated with younger age at onset (p<0.001). Duration of the disease decreased significantly with the length of the octapeptide repeat (p<0.001) when adjusting for age at onset. Conclusions: Our findings show significant inverse associations of the length of the PRNP octapeptide repeat with age at disease onset and disease duration in the spongiform encephalopathies.


Neurology | 2000

The α2-macroglobulin gene in AD A population-based study and meta-analysis

Mn Koster; Bart Dermaut; Marc Cruts; Jeanine J. Houwing-Duistermaat; Gerwin Roks; J. Tol; Alewijn Ott; Albert Hofman; G Munteanu; M.M.B. Breteler; C. M. van Duijn; C. Van Broeckhoven

Background: Whereas several authors recently reported a positive association between the α2-macroglobulin gene (A2M) and late-onset AD (LOAD), others were unable to replicate these findings. Early-onset AD (EOAD) is defined as onset age <65 years. Virtually all patients with LOAD are >65 years of age. Objective: To evaluate the role of A2M in AD, the authors conducted a population-based study of EOAD and LOAD as well as a meta-analysis of all studies conducted to date. Methods: Patients with EOAD (n = 100) were derived from a population-based study in four northern provinces of the Netherlands and the area of metropolitan Rotterdam. Patients with LOAD (n = 344) were drawn from the Rotterdam Study, a population-based prospective study on residents aged 55 years and over of a Rotterdam suburb in the Netherlands. Two polymorphisms were studied, A2M-I/D and A2M-Ile1000Val, in relation to the APOE ε4 allele (APOE*4). Results: No genotypic or allelic association was found for either polymorphism in the population-based series of patients with LOAD. In patients with EOAD without APOE*4, a significant increase of carriers of A2M-1000Val was found. The meta-analysis of available published case–control data on these polymorphisms in white and mixed ethnic populations yielded no significant differences between cases and controls. Pooling the Asian studies conducted to date showed a significant decrease in the frequency of A2M-D among patients. Conclusions: These results suggest that A2M is not genetically associated with LOAD in white patients or mixed populations as found in the United States. In these populations A2M does not have clinical relevance. From a scientific perspective, the findings on EOAD and Asian patients require replication and further research in the A2M region.


Annals of the Rheumatic Diseases | 2006

Association of matrilin-3 polymorphisms with spinal disc degeneration and osteoarthritis of the first carpometacarpal joint of the hand

Josine L. Min; Ingrid Meulenbelt; Naghmeh Riyazi; M. Kloppenburg; Jeanine J. Houwing-Duistermaat; Albert B. Seymour; C. M. van Duijn; P.E. Slagboom

Background: Seven polymorphisms in the matrilin-3(MATN3) gene were previously tested for genetic association with hand osteoarthritis in an Icelandic cohort. One of the variants, involving a conserved amino acid substitution (T303M; SNP5), was related to idiopathic hand osteoarthritis. Objectives: To investigate SNP5 and two other promising polymorphisms (rs2242190; SNP3, rs8176070; SNP6) for association with radiographic and symptomatic hand osteoarthritis phenotypes, as well as other heritable phenotypes. Methods: Polymorphisms were examined in two distinct cohorts of subjects: a population based sample from the Rotterdam study (nu200a=u200a809), and affected siblings from the genetics, osteoarthrosis and progression (GARP) study (nu200a=u200a382). Results: The originally described association of T303M with the hand osteoarthritis phenotype was not observed in the populations studied. In the Rotterdam sample, however, carrying the T allele of T303M conferred an odds ratio of 2.9 (95% confidence interval (CI), 1.2 to 7.3; pu200a=u200a0.02) for spinal disc degeneration. In the GARP study, carriers of the A allele of SNP6 had an odds ratio of 2.0 (95% CI, 1.3 to 3.1, pu200a=u200a0.004) for osteoarthritis of the first carpometacarpal joint (CMC1) as compared with the Rotterdam sample as a control group. Subsequent haplotype analysis showed that a common haplotype, containing the risk allele of SNP6, conferred a significant risk in sibling pairs with CMC1 osteoarthritis (odds ratiou200a=u200a1.7 (95% CI, 1.1 to 2.7, pu200a=u200a0.02)). Conclusions: These associations suggest that the MATN3 region also determines susceptibility to spinal disc degeneration and CMC1 osteoarthritis.


Annals of the Rheumatic Diseases | 2008

Allelic variation at the C-reactive protein gene associates to both hand osteoarthritis severity and serum high sensitive C-reactive protein levels in the GARP study

S.D. Bos; H. Suchiman; M. Kloppenburg; Jeanine J. Houwing-Duistermaat; M.-P. Hellio Le Graverand; A B Seymour; Herman M. Kroon; P.E. Slagboom; Ingrid Meulenbelt

Objective: To gain more insight into the role of genetic variation of the C-reactive protein (CRP) gene in serum CRP levels and osteoarthritis (OA). Methods: Serum high sensitive CRP (S-HsCRP) levels were measured in the Genetics of osteoARthritis and Progression (GARP) study. Furthermore, to assess genetic variation of the CRP gene, genotypes of five tagging single nucleotide polymorphisms were assessed in the GARP study and a random control sample. Results: A significant and consistent relation between S-HsCRP levels and observed haplotypes was identified. Additionally, a CRP haplotype, which also associated to a significantly higher expected phenotypic mean S-HsCRP level, was associated to severe hand OA. This haplotype was tagged by a single nucleotide polymorphism (rs3091244). Carriers of this allele have an increased risk for the presence of severe hand OA with an OR of 2.3 (95% confidence interval 1.2 to 4.3, pu200a=u200a0.009). Conclusions: A haplotype of the CRP gene, associated to high basal S-HsCRP level, is also associated to severity of hand OA, indicating that innate high basal S-HsCRP levels may influence OA onset.


Neurology | 2004

The occurrence of Guillain–Barré syndrome within families

Karin Geleijns; B. A. Brouwer; B. C. Jacobs; Jeanine J. Houwing-Duistermaat; C. M. van Duijn; P. A. van Doorn

This report describes 12 Dutch families of which at least two members have had Guillain-Barré syndrome (GBS). The authors observed an earlier onset of GBS in successive generations. The occurrence of GBS within families suggests a role for genetic factors in the pathogenesis of GBS.


Proceedings of the National Academy of Sciences of the United States of America | 2016

Community deworming alleviates geohelminth-induced immune hyporesponsiveness

Linda J. Wammes; Firdaus Hamid; Aprilianto E. Wiria; Linda May; Maria M. M. Kaisar; Margaretta A. Prasetyani-Gieseler; Yenny Djuardi; Heri Wibowo; Yvonne C. M. Kruize; Jaco J. Verweij; Sanne E. de Jong; Roula Tsonaka; Jeanine J. Houwing-Duistermaat; Erliyani Sartono; Adrian J. F. Luty; Taniawati Supali; Maria Yazdanbakhsh

Significance Chronic helminth infections are accompanied by profound immune regulation. In humans, helminth-induced immune reactivity has not been thoroughly investigated in trial settings. We assessed the effect of anthelmintic treatment on immune responses in a whole community in a placebo-controlled randomized controlled trial. We show increased immune responses to helminth-specific as well as unrelated antigens, in parallel with decreased expression of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), which is a molecule involved in putting the brake on immune activation. Deworming seems to lead to decreased immunoregulation and increased immune responsiveness. These findings are of importance regarding the suboptimal vaccine responses in helminth-endemic areas and also in anticipating the future rise in inflammatory diseases when helminth infections are increasingly controlled. In cross-sectional studies, chronic helminth infections have been associated with immunological hyporesponsiveness that can affect responses to unrelated antigens. To study the immunological effects of deworming, we conducted a cluster-randomized, double-blind, placebo-controlled trial in Indonesia and assigned 954 households to receive albendazole or placebo once every 3 mo for 2 y. Helminth-specific and nonspecific whole-blood cytokine responses were assessed in 1,059 subjects of all ages, whereas phenotyping of regulatory molecules was undertaken in 121 school-aged children. All measurements were performed before and at 9 and 21 mo after initiation of treatment. Anthelmintic treatment resulted in significant increases in proinflammatory cytokine responses to Plasmodium falciparum-infected red blood cells (PfRBCs) and mitogen, with the largest effect on TNF responses to PfRBCs at 9 mo—estimate [95% confidence interval], 0.37 [0.21–0.53], P value over time (Ptime) < 0.0001. Although the frequency of regulatory T cells did not change after treatment, there was a significant decline in the expression of the inhibitory molecule cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) on CD4+ T cells of albendazole-treated individuals, –0.060 [–0.107 to –0.013] and –0.057 [–0.105 to –0.008] at 9 and 21 mo, respectively; Ptime = 0.017. This trial shows the capacity of helminths to up-regulate inhibitory molecules and to suppress proinflammatory immune responses in humans. This could help to explain the inferior immunological responses to vaccines and lower prevalence of inflammatory diseases in low- compared with high-income countries.


Current Biology | 2016

The MC1R Gene and Youthful Looks.

Fan Liu; Merel A. Hamer; Joris Deelen; Japal S. Lall; Leonie C. Jacobs; Diana van Heemst; Peter Murray; Andreas Wollstein; Anton J. M. de Craen; Hae-Won Uh; Changqing Zeng; Albert Hofman; André G. Uitterlinden; Jeanine J. Houwing-Duistermaat; Luba M. Pardo; Marian Beekman; P. Eline Slagboom; Tamar Nijsten; Manfred Kayser; David A. Gunn

Looking young for ones age has been a desire since time immemorial. This desire is attributable to the belief that appearance reflects health and fecundity. Indeed, perceived age predicts survival [1] and associates with molecular markers of aging such as telomere length [2]. Understanding the underlying molecular biology of perceived age is vital for identifying new aging therapies among other purposes, but studies are lacking thus far. As a first attempt, we performed genome-wide association studies (GWASs) of perceived facial age and wrinkling estimated from digital facial images by analyzing over eight million SNPs in 2,693 elderly Dutch Europeans from the Rotterdam Study. The strongest genetic associations with perceived facial age were found for multiple SNPs in the MC1R gene (pxa0< 1xa0× 10(-7)). This effect was enhanced for a compound heterozygosity marker constructed from four pre-selected functional MC1R SNPs (pxa0= 2.69xa0× 10(-12)), which was replicated in 599 Dutch Europeans from the Leiden Longevity Study (pxa0= 0.042) and in 1,173 Europeans of the TwinsUK Study (pxa0= 3xa0× 10(-3)). Individuals carrying the homozygote MC1R risk haplotype looked on average up to 2 years older than non-carriers. This association was independent of age, sex, skin color, and sun damage (wrinkling, pigmented spots) and persisted through different sun-exposure levels. Hence, a role for MC1R in youthful looks independent of its known melanin synthesis function is suggested. Our study uncovers the first genetic evidence explaining why some people look older for their age and provides new leads for further investigating the biological basis of how old or young people look.


Journal of Thrombosis and Haemostasis | 2008

Selectin haplotypes and the risk of venous thrombosis: influence of linkage disequilibrium with the factor V Leiden mutation

S. Uitte De Willige; M. C. H. De Visser; Hans L. Vos; Jeanine J. Houwing-Duistermaat; Frits R. Rosendaal; R. M. Bertina

Summary.u2002 Background:u2002Selectins (E‐, L‐ and P‐selectin) and their most important counter‐receptor P‐selectin glycoprotein ligand (SELPLG) facilitate the interaction of platelets, leukocytes and endothelial cells at inflammatory sites. Selectin polymorphisms/haplotypes have been associated with cardiovascular disease. Objectives:u2002We investigated the association between haplotypes (H) of these four genes and deep venous thrombosis (DVT) risk. We additionally explored the effect of linkage disequilibrium (LD) with the nearby Factor V Leiden mutation (FVL). Furthermore, interactions between SELPLG polymorphisms and selectin polymorphisms were investigated. Patients/methods:u2002Leiden Thrombophilia Study (LETS) subjects were genotyped for 24 polymorphisms by TaqMan or PCR–RFLP, detecting all common haplotypes in four blocks. P‐selectin was analyzed in two blocks, upstream (SELPup) and downstream (SELPdown) of the recombination hotspot. Results:u2002In E‐ and L‐selectin, none of the haplotypes was associated with DVT risk. In SELPup, H2‐carriers had a 1.3‐fold increased risk (95% CI, 1.0–1.7), whereas H4‐carriers had a 1.4‐fold decreased risk (95% CI, 0.5–1.0). In SELPdown, H2‐carriers had a 1.3‐fold increased risk (95% CI, 1.0–1.7). Because of LD with FVL, we subsequently excluded all FVL‐carriers and all risks disappeared. Mutual adjustment within a logistic regression model resulted in disappearance of the risks for the SELP haplotypes, whereas FVL risk remained. Conclusions:u2002After adjustment for LD with FVL, none of the selectin haplotypes was associated with DVT risk, showing that the increased risks of the selectin haplotypes were a reflection of the effect of FVL on thrombosis risk.

Collaboration


Dive into the Jeanine J. Houwing-Duistermaat's collaboration.

Top Co-Authors

Avatar

C. M. van Duijn

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Erliyani Sartono

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. C. van Swieten

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Maria Yazdanbakhsh

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

P.E. Slagboom

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

M. Kloppenburg

Loyola University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Albert Hofman

Battelle Memorial Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge